ArticleJournal of medical biochemistry2026
Biochemical monitoring-guided clinical management improves inflammatory and oxidative stress profiles in sudden sensorineural hearing loss.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sudden sensorineural hearing loss (SSNHL) is strongly linked to dysregulated inflammatory and oxidative stress pathways. However, the biochemical impact of applying these biomarkers to guide clinical management remains unclear. This study evaluated whether inflammationand oxidative stress-based biochemical monitoring can optimize treatment responses and improve clinical outcomes in SSNHL. Methods: A total of 102 patients with SSNHL were randomly allocated to either a routine-management group or a biomarker-guided management group. Serial serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), malondialdehyde (MDA), and superoxide dismutase (SOD) were quantified by ELISA before and after intervention. Hearing thresholds and quality-of-life indices were assessed concurrently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.